Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2886 | Phlebotomy Wiki | 1.00 |
| drug1918 | Inactivated convalescent plasma Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Convalescent plasma is a way to provide passive immunity to a person exposed to an infectious agent. It has been used as a therapeutic tool for emerging viral infections without specific treatment and with high morbidity and mortality, such as Influenza H1N1, H5N1, H7N9, Ebola, MERS, SARS-CoV1, and even SARS-Cov2, with satisfactory results regarding evolution clinic of patients treated and without significant adverse events reported. One of its main advantages of convalescent plasma is to generate a rapid immune response (even faster than a vaccine), against a pathogen that circulates in a specific geographic area, probably common for both donor and recipient.
Description: To assess the efficacy in reducing mortality in CoViD-19 patients treated with inactivated convalescent plasma together with the support treatment selected by the respective hospital
Measure: Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment Time: Over a period of 28 daysDescription: Number of Participants with resolution of fever (<38ºC temperature)
Measure: Clinical evolution Time: Over a period of 28 daysDescription: The clinical improvement will be established with a two-point improvement within this seven categories (recommended by World Organization Health-WHO): 1) Not hospitalized, with resumption of normal activities 2) Not hospitalized, but unable to resume normal activities 3) Hospitalized that does not require supplemental oxygen 4) Hospitalized requiring supplemental oxygen 5) Hospitalized requiring high-flow nasal oxygen therapy, non-invasive mechanical ventilation, or both 6) Hospitalized requiring extracorporeal membrane oxygenation, invasive mechanical ventilation, or both 7) death
Measure: Clinical evolution by seven-parameter ordinal scale Time: 3, 7, 14 and 28 daysDescription: Evolution by SOFA (Sequential Organ Failure Assessment), The range is between 0 and 24 points, with the highest scores being indicators of a more serious illness
Measure: Multi-organ failure progression Time: 3, 7, 14 and 28 daysDescription: Compare the change in hemoglobin concentration at 3, 7, 14 and 28 days after treatment
Measure: Change in hemoglobin concentration Time: 3, 7, 14 and 28 daysDescription: Compare the change in blood cell count at 3, 7, 14 and 28 days after treatment
Measure: Change in blood cell count Time: 3, 7, 14 and 28 daysDescription: Compare the change in Serum creatinine concentration at 3, 7, 14 and 28 days after treatment
Measure: Change in serum creatinine level Time: 3, 7, 14 and 28 daysDescription: Compare the change in aspartate aminotransferase level at 3, 7, 14 and 28 days after treatment
Measure: Change in aspartate aminotransferase level Time: 3, 7, 14 and 28 daysDescription: Compare the change in Alanine aminotransferase levels at 3, 7, 14 and 28 days after treatment
Measure: Change in alanin aminotransferase level Time: 3, 7, 14 and 28 daysDescription: Compare the change in bilirubin levels at 3, 7, 14 and 28 days after treatment
Measure: Change in bilirubin level Time: 3, 7, 14 and 28 daysDescription: Compare the change in lactate dehydrogenase levels at 3, 7, 14 and 28 days after treatment
Measure: Change in lactate dehydrogenase level Time: 3, 7, 14 and 28 daysDescription: Compare the change in creatine kinase levels at 3, 7, 14 and 28 days after treatment
Measure: Change in creatine kinase level Time: 3, 7, 14 and 28 daysDescription: Compare the change in creatine kinase MB levels at 3, 7, 14 and 28 days after treatment
Measure: Change in creatine kinase MB level Time: 3, 7, 14 and 28 daysDescription: Compare the change in C reactive protein concentration at 3, 7, 14 and 28 days after treatment, in mg/L
Measure: Change in C reactive protein concentration Time: 3, 7, 14 and 28 daysDescription: Compare the change in D Dimer concentration at 3, 7, 14 and 28 days after treatment
Measure: Change in D Dimer concentration Time: 3, 7, 14 and 28 daysDescription: Compare the change in procalcitonin concentration at 3, 7, 14 and 28 days after treatment
Measure: Change in Procalcitonin concentration Time: 3, 7, 14 and 28 daysDescription: Compare the change in IL6 level at 3, 7, 14 and 28 days after treatment
Measure: Change in IL6 level Time: 3, 7, 14 and 28 daysDescription: Resolution of chest radiography imaging findings (example, bilateral, peripheral and basal predominant ground-glass opacity, consolidation, or both)
Measure: Radiography imaging Time: Over a period of 60 daysDescription: Resolution of tomography imaging (example, patches located in the subpleural regions of the lung)
Measure: Tomography imaging Time: Over a period of 60 daysDescription: Arterial oxygen partial pressure (PaO2) in mmHg / Inspired fraction of oxygen (FIO2) ratio
Measure: Assessment of oxygenation Time: 3, 7, 14 and 28 daysDescription: Viral Load Quantification
Measure: Viral Load Time: 0, 3, 7 days and until hospital discharge or a maximum of 60 days whichever comes firstDescription: Neutralizing antibody anti SARS-CoV-2 titer evolution
Measure: Antibody titer Time: Day 0, Day 3 and Day 7Description: Number of days without use of Oxygen
Measure: Oxygen-free days through Day 60 Time: Until hospital discharge or a maximum of 60 days whichever comes firstDescription: Number of days without use of mechanical ventilation
Measure: Mechanical ventilation-free days through Day 28 Time: Until hospital discharge or a maximum of 28 days whichever comes firstDescription: Time outside of ICU, in days
Measure: Intensive Care Unit (ICU)-free days through Day 28 Time: Until hospital discharge or a maximum of 28 days whichever comes firstDescription: Time outside of the hospital, in days
Measure: Hospital-free days through Day 60 Time: Until hospital discharge or a maximum of 60 days whichever comes firstDescription: Occurrence of adverse events during inactivated convalescent plasma transfusion, classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0
Measure: Incidence of adverse events Time: Up to 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports